🚨 URGENT: 11-YEAR-OLD CATE FIGHTING A RARE GENETIC NIGHTMARE—SHE NEEDS A BONE MARROW DONOR MATCH NOW TO STOP CANCER BEFORE IT STARTS! 😭🩸💉🙏

Sweet Cate Hargett has Telomere Biology Disorder (TBD)—a devastating rare condition causing super-short telomeres that wreck her bone marrow and organs. On top of that, she has a TP53 mutation (the “guardian of the genome” gone wrong), putting her at HIGH RISK of developing deadly cancer.

Chemo? Radiation? Not options for her—her fragile body couldn’t handle them. The BEST shot at preventing cancer and saving her life? A bone marrow transplant to replace her failing marrow with healthy donor cells.

But she doesn’t have a match yet. Family, friends, St. Jude teams, and Team Telomere are rallying—swab drives at schools, pharmacies, and events—but time is critical. Every new person on the registry could be her miracle.

This brave girl deserves a fighting chance. She’s already endured so much—now the world needs to step up.

The full story, how to register (Be The Match/NMDP links), local drives, and why Cate’s case is so urgent are in the link below. One swab could save her life—or someone else’s.💔❤️

A determined search is underway for a bone marrow donor match for 11-year-old Cate Hargett, an Alabama girl battling Telomere Biology Disorder (TBD), a rare genetic condition that has left her at elevated risk for life-threatening cancer. With conventional cancer treatments like chemotherapy and radiation off the table due to her fragile health, a stem cell transplant represents her strongest preventive option.

Cate was diagnosed with TBD, a spectrum of inherited disorders caused by mutations impairing telomere maintenance—the protective caps on chromosomes that shorten with age and cell division. In TBD patients, telomeres are abnormally short from birth, leading to accelerated cellular aging and failure in rapidly dividing tissues like bone marrow, lungs, liver, and skin. Bone marrow failure is a hallmark, affecting up to 80% of pediatric cases, often progressing to severe pancytopenia or myelodysplastic syndrome.

Compounding her challenges, genetic testing revealed a TP53 mutation. Known as the “guardian of the genome,” TP53 normally prevents damaged cells from proliferating by triggering repair, cell cycle arrest, or apoptosis. Mutations disrupt this safeguard, dramatically raising cancer risk—particularly hematologic malignancies, solid tumors like head and neck squamous cell carcinoma, and others. In TBD patients, the combination of short telomeres and TP53 alterations creates a high-risk environment for clonal evolution and oncogenic transformation.

Cate’s family and medical team at St. Jude Children’s Research Hospital have emphasized proactive intervention. If cancer develops, standard therapies would be poorly tolerated due to her underlying telomere dysfunction and organ vulnerabilities. Bone marrow (hematopoietic stem cell) transplant offers the potential to introduce healthy donor cells capable of normal telomere function and blood production, potentially halting progression to malignancy or bone marrow failure.

The transplant would ideally come from an unrelated matched donor, as related family members may carry subclinical variants or shortened telomeres themselves—current guidelines recommend genetic screening of potential related donors to avoid transmitting the disorder. Cate currently lacks a match, prompting widespread appeals through social media, community swab drives, and partnerships with organizations like Team Telomere and the National Marrow Donor Program (NMDP, formerly Be The Match).

Team Telomere, a nonprofit dedicated to supporting those affected by TBDs, has highlighted Cate’s case during Rare Disease Month observances. The group provides resources, including diagnosis guidelines and connections to transplant networks, while stressing the importance of registry expansion. Joining the donor registry involves a simple cheek swab to test HLA (human leukocyte antigen) markers—key for matching. The process is free, painless, and open to healthy individuals aged 18-44 (with some extensions), though matches are rare and commitment is required only if selected.

Community efforts have included drives at schools like Pillow Academy, local pharmacies, and events organized by supporters. Posts from family friends and institutions urge registration, noting that increasing registry diversity improves odds for patients with uncommon HLA types. NMDP maintains the world’s largest registry, but ethnic and genetic minorities remain underrepresented, complicating matches for many.

TBDs, once primarily associated with dyskeratosis congenita (characterized by nail dystrophy, skin pigmentation changes, and oral leukoplakia), are now recognized as a broader spectrum. Mutations in genes like TERT, TERC, DKC1, TINF2, and others impair telomerase activity or telomere protection. Symptoms vary widely—some patients present in childhood with bone marrow issues, others later with pulmonary fibrosis or liver cirrhosis. Cancer predisposition is significant, with TP53 mutations further elevating risks, as seen in overlapping syndromes like Li-Fraumeni.

Cate’s story illustrates the real-world impact of these rare conditions. At 11, she navigates frequent medical visits, monitoring for organ complications, and the emotional weight of her prognosis. Supporters describe her as resilient and beloved, with childhood experiences shaped by hospital routines rather than typical play. Her case has galvanized local action, with calls to “join for Cate or another waiting patient.”

Transplant success in TBD patients has improved with refined conditioning regimens to minimize toxicity, though risks remain higher than in standard cases due to underlying fragility. Reduced-intensity protocols and careful donor selection have yielded long-term engraftment in select reports. For Cate, the goal is preemptive: transplant before cancer or severe failure takes hold.

The urgency stems from TBD’s progressive nature. Short telomeres drive replicative stress, activating DNA damage pathways (including p53), leading to senescence, apoptosis, or malignant escape. In patients with co-occurring TP53 mutations, clonal hematopoiesis can accelerate toward leukemia or solid tumors.

Public health advocates note that expanding the donor pool saves lives across diseases—leukemia, lymphoma, sickle cell, and rare disorders like TBD. NMDP reports thousands await matches, with odds improving dramatically through new registrations.

Cate’s family continues sharing updates via social media and community networks, expressing gratitude for support while pleading for more donors. No specific fundraiser links dominate reports, but emphasis remains on registry participation over financial aid.

As searches persist, Cate’s fight spotlights gaps in rare disease awareness and donor diversity. Medical experts from institutions like the National Cancer Institute and ASH continue advancing TBD research, including telomere-targeted therapies and better screening. For now, the most immediate hope lies in finding that one compatible donor.

Anyone interested in joining the registry can visit bethematch.org or nmdp.org. A simple swab could make the difference—for Cate or the next patient in need.